• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.

作者信息

Aleisa Ahmad I, Plante John G, Hsia Ling-Lun B

机构信息

Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina.

Department of Dermatology, King Saud Medical City, Riyadh, Saudi Arabia.

出版信息

JAAD Case Rep. 2020 Jun 16;6(8):727-730. doi: 10.1016/j.jdcr.2020.06.008. eCollection 2020 Aug.

DOI:10.1016/j.jdcr.2020.06.008
PMID:32715063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7369521/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e5c/7369521/65d927c1cc5d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e5c/7369521/8f649e387231/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e5c/7369521/fd4469f7a7a3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e5c/7369521/65d927c1cc5d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e5c/7369521/8f649e387231/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e5c/7369521/fd4469f7a7a3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e5c/7369521/65d927c1cc5d/gr4.jpg

相似文献

1
A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.1例在用Janus激酶抑制剂托法替布治疗期间发生的伴有淋巴管浸润的侵袭性鳞状细胞癌。
JAAD Case Rep. 2020 Jun 16;6(8):727-730. doi: 10.1016/j.jdcr.2020.06.008. eCollection 2020 Aug.
2
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.一名正在使用Janus激酶抑制剂鲁索替尼的患者发生侵袭性鳞状细胞癌。
JAAD Case Rep. 2018 Apr 30;4(5):455-457. doi: 10.1016/j.jdcr.2018.01.001. eCollection 2018 Jun.
3
Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.托法替布治疗类风湿关节炎临床项目中的非黑色素瘤皮肤癌分析
Clin Exp Rheumatol. 2017 Jul-Aug;35(4):614-622. Epub 2017 Feb 27.
4
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.托法替布，一种口服的 Janus 激酶抑制剂，用于治疗拉丁美洲类风湿关节炎患者：3 期和长期扩展研究的汇总疗效及安全性分析
Reumatol Clin. 2017 Jul-Aug;13(4):201-209. doi: 10.1016/j.reuma.2016.04.010. Epub 2016 Jun 15.
5
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.托法替布，一种口服的 Janus 激酶抑制剂，作为单药治疗或与背景甲氨蝶呤联合使用，用于日本类风湿关节炎患者：一项开放标签的长期扩展研究。
Arthritis Res Ther. 2016 Jan 28;18:34. doi: 10.1186/s13075-016-0932-2.
6
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.托法替布：首个用于治疗类风湿关节炎的 Janus 激酶（JAK）抑制剂。
Ann Pharmacother. 2013 Nov;47(11):1524-31. doi: 10.1177/1060028013512790.
7
Selective in situ protein expression profiles correlate with distinct phenotypes of basal cell carcinoma and squamous cell carcinoma of the skin.皮肤基底细胞癌和鳞状细胞癌的选择性原位蛋白表达谱与不同表型相关。
Histol Histopathol. 2013 Jul;28(7):941-54. doi: 10.14670/HH-28.941. Epub 2013 Feb 28.
8
Peritumoral fibrosis in basal cell and squamous cell carcinoma mimicking perineural invasion: potential pitfall in Mohs micrographic surgery.基底细胞癌和鳞状细胞癌中的瘤周纤维化酷似神经周围浸润：莫氏显微外科手术中的潜在陷阱
Dermatol Surg. 2005 Sep;31(9 Pt 1):1101-6. doi: 10.1097/00042728-200509000-00003.
9
Lamin expression in normal human skin, actinic keratosis, squamous cell carcinoma and basal cell carcinoma.核纤层蛋白在正常人类皮肤、光化性角化病、鳞状细胞癌和基底细胞癌中的表达。
Br J Dermatol. 2003 Jan;148(1):102-9. doi: 10.1046/j.1365-2133.2003.05026.x.
10
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.口服Janus激酶抑制剂托法替布治疗类风湿关节炎患者的心血管安全性研究结果
Semin Arthritis Rheum. 2016 Dec;46(3):261-271. doi: 10.1016/j.semarthrit.2016.05.014. Epub 2016 Jun 2.

引用本文的文献

1
Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.利用美国食品和药物管理局不良事件报告系统分析 Janus 激酶抑制剂与恶性皮肤肿瘤之间的关联。
Int J Clin Pharm. 2023 Dec;45(6):1483-1491. doi: 10.1007/s11096-023-01634-5. Epub 2023 Aug 22.
2
Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma.皮肤鳞状细胞癌的生物学特性与治疗进展
Cancers (Basel). 2021 Nov 11;13(22):5645. doi: 10.3390/cancers13225645.
3
Janus Kinase Inhibitors and Non-Melanoma Skin Cancer.

本文引用的文献

1
Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.关于靶向JAK/STAT通路药物在特应性皮炎、白癜风和斑秃中应用的范围综述
Dermatol Ther (Heidelb). 2019 Dec;9(4):655-683. doi: 10.1007/s13555-019-00329-y. Epub 2019 Oct 13.
2
Off-label studies on tofacitinib in dermatology: a review.托法替布在皮肤科的非标签研究综述
J Dermatolog Treat. 2021 Jun;32(4):399-409. doi: 10.1080/09546634.2019.1673877. Epub 2019 Oct 3.
3
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Janus 激酶抑制剂与非黑素瘤皮肤癌。
Curr Treat Options Oncol. 2021 Jan 9;22(2):11. doi: 10.1007/s11864-020-00815-y.
接受 Janus 激酶抑制剂芦可替尼治疗真性红细胞增多症后出现侵袭性 Merkel 细胞癌。
In Vivo. 2019 Sep-Oct;33(5):1667-1669. doi: 10.21873/invivo.11653.
4
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.托法替布治疗类风湿关节炎长达 9.5 年的安全性和疗效：一项全球性、开放标签、长期扩展研究的最终结果。
Arthritis Res Ther. 2019 Apr 5;21(1):89. doi: 10.1186/s13075-019-1866-2.
5
Development of Aggressive Squamous Cell Carcinoma With Perineural Invasion During Ruxolitinib Treatment.芦可替尼治疗期间发生伴神经周围侵犯的侵袭性鳞状细胞癌
Dermatol Surg. 2019 May;45(5):734-736. doi: 10.1097/DSS.0000000000001626.
6
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.一名正在使用Janus激酶抑制剂鲁索替尼的患者发生侵袭性鳞状细胞癌。
JAAD Case Rep. 2018 Apr 30;4(5):455-457. doi: 10.1016/j.jdcr.2018.01.001. eCollection 2018 Jun.
7
Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.托法替布治疗类风湿关节炎临床项目中的非黑色素瘤皮肤癌分析
Clin Exp Rheumatol. 2017 Jul-Aug;35(4):614-622. Epub 2017 Feb 27.
8
Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology.皮肤鳞状细胞癌高危特征综述以及美国癌症联合委员会与美国国立综合癌症网络肿瘤学临床实践指南之间的差异
Head Neck. 2017 Mar;39(3):578-594. doi: 10.1002/hed.24580. Epub 2016 Nov 24.
9
Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.自身免疫性疾病和非黑色素瘤皮肤癌病史患者使用免疫抑制剂和生物制剂与非黑色素瘤皮肤癌的风险
JAMA Dermatol. 2016 Feb;152(2):164-72. doi: 10.1001/jamadermatol.2015.3029.
10
Iatrogenic immunosuppression and cutaneous malignancy.医源性免疫抑制与皮肤恶性肿瘤。
Clin Dermatol. 2011 Nov-Dec;29(6):602-13. doi: 10.1016/j.clindermatol.2011.08.009.